Print

ChemoCentryx, Inc. (CCXI) Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development  
1/7/2013 9:48:18 AM

MOUNTAIN VIEW, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the initiation of a Phase I clinical trial for CCX507, the Company's novel, wholly-owned inhibitor of the chemokine receptor known as CCR9. The double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of CCX507 in healthy adult subjects.